https://orcid.org/0000-0002-7559-7521
References
- Rashid M, Rajan AK, Chhabra M, et al. Levetiracetam and cutaneous adverse reactions: a systematic review of descriptive studies. Seizure. 2020;75:101–109. doi: 10.1016/j.seizure.2020.01.002.
- Frantz R, Huang S, Are A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management. Medicina 2021;57(9):895. doi: 10.3390/medicina57090895.
- Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60–68. doi: 10.1038/clpt.2009.252.
- Estébanez A, Sáez‐Martín LC, Muñoz JI, et al. Levetiracetam-induced pediatric toxic epidermal necrolysis successfully treated with etanercept. Pediatr Dermatol. 2020;37(4):701–705. doi: 10.1111/pde.14179.
- Noguchi Y, Takaoka M, Hayashi T, et al. Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of a Japanese pharmacovigilance database. Epilepsia. 2020;61(9):1979–1989. doi: 10.1111/epi.16626.